Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00980005 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,116
- Enrollment target
NCT00980005: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00980005 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 2,116 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (174% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00980005, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,116 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK1557482A.
Primary Outcome
The three strains assessed were A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) and B/Brisbane/60/2008. Titers were expressed as geometric mean antibody titers (GMTs).
Interventions
- BIOLOGICAL Fluzone®
- BIOLOGICAL GSK investigational vaccine GSK1557482A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,116 participants |
| Start Date | 2009-10-13 |
| Est. Completion | 2010-06-17 |
| Phase | Phase 3 |
What the finished NCT00980005 record still lists
NCT00980005 is an interventional study that assigns participants to a tested intervention. Its 2,116 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (174% higher).
The record links to 0 conditions, and to 2 interventions - of which Fluzone® is the first listed.
NCT00980005 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00980005 about?
NCT00980005 is a clinical study titled "Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children". The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK1557482A.
What is the current status of trial NCT00980005?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,116 participants. The study started on 2009-10-13. Estimated completion is 2010-06-17.
What interventions are being tested in trial NCT00980005?
The interventions under investigation include: Fluzone® (BIOLOGICAL), GSK investigational vaccine GSK1557482A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00980005?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00980005's enrollment target sits among peer trials
2,116 98th of 2000 higher than 1,903 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05916430 · 2,120 participants
Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement
- NCT05681624 · 2,124 participants · NA
Maternal Oxygen Supplementation for Intrauterine Resuscitation
- NCT05967273 · 2,106 participants · NA
CirrhosisRx CDS System
- NCT07431281 · 2,130 participants · Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI